Articles

Potential Lilly drug doubles good cholesterol

Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.

Read More

Potential Effient rival shows promise in study

A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.

Read More

Lilly, Amylin agree to end diabetes partnership

Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.

Read More

Q&A

Sherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University, is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference Oct. 22-26 at the Indiana Convention Center.

Read More

Health regulatory leaders ready to flock to city

The top event for regulatory professionals in the health care industry is headed to Indianapolis next month. The annual conference of the Regulatory Affairs Professionals Society, or RAPS, is expected to draw thousands of members representing 120 companies and organizations.

Read More

FDA gets new report on Lilly diabetes drug

Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.

Read More

R&D spending soars above value of new drugs

To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.

Read More

Timing good for 2-in-1 biotech drugs

Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.

Read More

Amylin sues Lilly over drug development deal

Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.

Read More

Two wins to bring Lilly modest sales

Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.

Read More